Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1235 Letrozole <1 mg/mL 57 mg/mL <1 mg/mL
S1188 Anastrozole <1 mg/mL 59 mg/mL 59 mg/mL
S1196 Exemestane <1 mg/mL 54 mg/mL 15 mg/mL
S2208 Formestane <1 mg/mL 61 mg/mL <1 mg/mL
S1672 Aminoglutethimide <1 mg/mL 20 mg/mL 7 mg/mL
Catalog No. Information Product Use Citations Product Validations


Letrozole is a third generation inhibitor of aromatase with IC50 of 0.07-20 nM in cell-free assays.It has no effect on the plasma levels of 17α-OH progesterone, thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or androstenedione and does not affect normal urine electrolyte excretion or thyroid function in clinical studies.



Anastrozole is a third-generation nonsteroidal selective aromatase inhibitor. It may offer greater selectivity compared with other aromatase inhibitors, being without any intrinsic endocrine effects and with no apparent effect on the synthesis of adrenal steroids.



Exemestane is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.



Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM.



Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.

Tags: aromatase inhibition | aromatase breast cancer | estrogen aromatase | aromatase inhibitors for men | aromatase inhibitors breast cancer | aromatase activity | aromatase deficiency | aromatase inhibitor therapy | aromatase inhibitors supplement | aromatase p450 | aromatase inhibitors for women | aromatase assay | aromatase inhibitors list | aromatase inhibitors mechanism | aromatase inhibitors drugs | aromatase pathway | aromatase inhibitor review